Please ensure Javascript is enabled for purposes of website accessibility

Why Progenics Pharmaceuticals, Inc. Shares Soared Today

By Brian Orelli, PhD – Jul 20, 2016 at 4:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech scored FDA approval for the oral version of its opioid-induced constipation drug, Relistor.

Image source: Getty Images.

What: Progenics Pharmaceuticals (PGNX) is up 23% at 3:35 p.m. ET after announcing yesterday after the closing bell that the Food and Drug Administration approved an oral version of the company's opioid-induced constipation drug, Relistor.

So what: In 2011, the biotech licensed Relistor to Salix Pharmaceuticals, which was bought by Valeant Pharmaceuticals (BHC 2.99%) last year. Valeant Pharmaceuticals already sells an injectable version of Relistor, but it isn't a particularly big seller with sales of just $16.6 million in the first quarter, netting Progenics Pharmacetuicals $2.2 million in royalty revenue. The new oral version, which Valeant will start selling in the third quarter, will be easier for patients to take than the injected version, resulting in higher sales.

As part of the deal with Salix, Progenics Pharmaceuticals is due $50 million upon approval of oral Relistor in the U.S. and could get up to $200 million in commercial milestones based on annual sales. The royalty rate also increases as sales increase with tiers at annual sales of $100 million, $400 million, and $500 million.

Now what: Progenics management believes the oral version of Relistor could be a $1-billion-plus opportunity for Valeant, according to an analyst report from Guggenheim's Louise Chen. Even if that's a bit of a stretch, half of that estimate would be a welcome increase in royalty revenue for Progenics Pharmaceuticals to help develop the rest of its pipeline.

Brian Orelli has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Valeant Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Bausch Health Companies Stock Quote
Bausch Health Companies
BHC
$7.93 (2.99%) $0.23
Progenics Pharmaceuticals Stock Quote
Progenics Pharmaceuticals
PGNX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.